Xiaohua Wu
Fudan University
Emerging Leaders
not ranked
Current Leaders
#3645 pts
All-Time Leaders
#2,59414 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2012. 9 trials as lead/chair. How it works →
Trials led — by scientific impact
Famitinib Malate Plus Anti-PD1 Therapy (SHR-1210) in Advanced Renal Cell Carcinoma, Urothelial Carcinoma, Advanced Cervical Cancer, Relapse Ovarian Cancer, Endometrial Cancer: Multi-institutional, Open-label, Phase 2 Trial
Phase 2UnknownJiangsu HengRui Medicine Co., Ltd.
4
impact
A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-Risk Early Stage Cervical Cancer (SHAPE)
N/ACompletedCanadian Cancer Trials GroupStudy Chair
4
impact
A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-B01D1 for Injection in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
2
impact
A Multi-center, Phase Ⅱ Clinical Trial of Chiauranib Plus Chemotherapy in Relapsed/Refractory Ovarian Cancer
Phase 2CompletedChipscreen Biosciences, Ltd.
2
impact
An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid Tumors
Phase 2RecruitingShanghai Jiatan Pharmatech Co., Ltd
1
impact
An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
Phase 2UnknownGuangzhou Gloria Biosciences Co., Ltd.
0
impact
A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer
Phase 3ActiveImpact Therapeutics, Inc.
0
impact
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN033 in Chinese Subjects with Advanced Malignant Tumors
Phase 2Not Yet RecruitingJiangsu Alphamab Biopharmaceuticals Co., Ltd
0
impact
0
impact
A Phase 1, Multicenter, Open-label First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of SKB518 in Subjects With Advanced Solid Tumors
Phase 1RecruitingSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Study Chair
0
impact
A Phase I Clinical Study to Evaluate Safety and Efficacy of C-TIL052A Cell Therapy (Autologous Tumor Infiltrating Lymphocytes Injection Combined With IL-2) in Subjects With Persistent, Recurrent and/or Metastatic Cervical Cancer
Phase 1UnknownFudan University
0
impact
An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Phase 2Recruiting3D Medicines (Sichuan) Co., Ltd.
0
impact
0
impact
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced and Relapsed Ovarian Cancer After 3 or 4 Previous Chemotherapies
Phase 2CompletedZai Lab (Shanghai) Co., Ltd.
0
impact